1.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 13 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MK-8669-011, AP23573-07-302, NCT00538239
|
|
2.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AP23573-04-201, NCT00086125
|
|
3.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 15 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AP23573-04-202, EudraCT #:2004-002231-92, NCT00093080
|
|
4.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AP23573-04-204, NCT00110188
|
|
5.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AP23573-04-203, NCT00122343
|
|
6.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MK-8669-009, AP23573-08-207, NCT00736970
|
|
7.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MK-8669-007, AP23573-07-205, NCT00739830
|
|
8.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: Over 18
Sponsor: Other
Protocol IDs: I192, CAN-NCIC-IND192, ARIAD-CAN-NCIC-IND192, CDR0000614597, IND192, NCT00770185
|
|
9.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2008_572, MK8669-002, NCT00777959
|
|
10.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 8669-021, 2008_599, NCT00818675
|
|
11.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 13 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2009_688, MK8669-030, NCT01010672
|
|
12.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MK-8669-041, NCT01234857
|
|
13.
|
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AP23573-02-101, NCT00060632
|
|
14.
|
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AP23573-02-102, NCT00060645
|
|
15.
|
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AP23573-04-103, NCT00087451
|
|
16.
|
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AP23573-05-106, NCT00112372
|
|
17.
|
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AP23573-05-107, NCT00288431
|
|
18.
|
Phase: Phase I
Type: Treatment
Status: Completed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2008_011, MK8669-003, NCT00694083
|
|
19.
|
Phase: Phase I
Type: Treatment
Status: Completed
Age: 1 to 17
Sponsor: Pharmaceutical / Industry
Protocol IDs: AP23573-07-110, SUN08-01, NCT00704054
|
|
20.
|
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2008_538, MK8669-004, NCT00730379
|
|
21.
|
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AP23573-08-111, NCT00781846
|
|
22.
|
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2009_569, MK8669-037, NCT00874731
|
|
23.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2009_706, MK8669-046, NCT01043887
|
|
24.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MK-8669-044, 2010_511, NCT01071304
|
|
25.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: MK-8669-059, NCT01380184
|
Mobile | Español
